Skip to content
10-K

Annual Report

Alaunos Therapeutics, Inc. TCRT

0001193125-26-134720

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 31, 2026 2.38M sh
Shares Diluted FY 2025 · Dec 31, 2025 1.95M sh
Shares Diluted FY 2025 · Dec 31, 2024 1.6M sh
Capex FY 2025 · Dec 31, 2025 $98K
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$2.87M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$4.97M
Cash And Equivalents FY 2025 · Dec 31, 2025 $1.39M
Cash And Equivalents FY 2025 · Dec 31, 2024 $1.09M
Stockholders Equity FY 2025 · Dec 31, 2025 $2.15M
Stockholders Equity FY 2025 · Dec 31, 2024 $2.06M
Stockholders Equity FY 2025 · Dec 31, 2023 $6.31M
Current Liabilities FY 2025 · Dec 31, 2025 $813K
Current Liabilities FY 2025 · Dec 31, 2024 $692K
Total Liabilities FY 2025 · Dec 31, 2025 $813K
Total Liabilities FY 2025 · Dec 31, 2024 $692K
Current Assets FY 2025 · Dec 31, 2025 $1.99M
Current Assets FY 2025 · Dec 31, 2024 $2.76M
Total Assets FY 2025 · Dec 31, 2025 $2.97M
Total Assets FY 2025 · Dec 31, 2024 $2.76M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.20
Eps Diluted FY 2025 · Dec 31, 2024 −$2.92
Eps Basic FY 2025 · Dec 31, 2025 −$2.20
Eps Basic FY 2025 · Dec 31, 2024 −$2.92
Sga Expense FY 2025 · Dec 31, 2025 $2.87M
Sga Expense FY 2025 · Dec 31, 2024 $4.46M
Rd Expense FY 2025 · Dec 31, 2025 $1.36M
Rd Expense FY 2025 · Dec 31, 2024 $362K
Net Income FY 2025 · Dec 31, 2025 −$4.18M
Net Income FY 2025 · Dec 31, 2024 −$4.68M
Net Income restated FY 2025 · Dec 31, 2023 −$4.68M
Operating Income FY 2025 · Dec 31, 2025 −$4.23M
Operating Income FY 2025 · Dec 31, 2024 −$4.81M
Revenue FY 2025 · Dec 31, 2025 $5K
Revenue FY 2025 · Dec 31, 2024 $10K